Biocell Center

Biocell Center is an Italy-based biotechnology and biological-materials banking company focused on the collection, processing, cryopreservation, and private storage of stem cells obtained from amniotic fluid. Its activities are associated particularly with samples collected during genetic amniocentesis, linking the company’s service model to prenatal healthcare and the preservation of biological material for possible future medical research or therapeutic use. The company’s principal distinction is its reported role in establishing dedicated banking infrastructure for amniotic-fluid stem cells. In 2008, Biocell Center opened what has been described as the first amniotic-fluid stem-cell bank in the world. In 2009, it opened the first such bank in the United States intended for private storage of stem cells collected during genetic amniocentesis. These developments positioned the company in a specialized segment of the broader private stem-cell-banking industry, separate from more established cord-blood banking services. Biocell Center’s Italian operations have been associated with locations in Busto Arsizio and Milan. The company has also been described as maintaining or operating international subsidiaries in Lugano, Switzerland, and Natick, Massachusetts, in the Boston area. This geographic structure supports an international operating model spanning sample collection, laboratory services, private banking, and scientific collaboration. The company’s work extends beyond storage services. Reference material identifies collaborations with Harvard University and the Caritas Christi Health Care hospital network on research involving amniotic stem cells. These relationships reflect an effort to develop the scientific and clinical understanding of amniotic-fluid-derived cells, including their potential characteristics and applications. The available reference material does not establish specific approved therapies, commercialized medicines, or clinical outcomes attributable to Biocell Center. Management and scientific leadership identified in the available material include company president Marco Reguzzoni and scientific director Giuseppe Simoni. Because the supplied sources do not provide a current corporate website, detailed ownership information, financial data, a definitive founding date, or a complete chronology of later activities, those aspects remain unspecified. Biocell Center is best characterized as a specialized international stem-cell banking and research company whose brand proposition combines private biological preservation with participation in amniotic-stem-cell research.

Biocell Center emerged in the specialized field of amniotic-fluid stem-cell preservation. Unlike conventional blood-component or cord-blood banks, the company’s focus is the collection and storage of stem cells associated with amniotic fluid, including material obtained during genetic amniocentesis. This focus places the company within a technically narrow area of private biological banking and prenatal sample management. A major reported milestone occurred in 2008, when Biocell Center opened the first dedicated amniotic-fluid stem-cell bank in the world. The move gave the company an early institutional position in a field that was still developing scientifically and commercially. Establishing a dedicated bank required the integration of sample collection procedures, laboratory processing, cryogenic preservation, record management, and private customer storage. The company’s model was therefore not limited to research support; it also offered a preservation service directed at families seeking to retain biological material for possible future use. In 2009, Biocell Center expanded this model into the United States by opening the first U.S. amniotic-fluid stem-cell bank for private storage of cells obtained during genetic amniocentesis. The U.S. operation was associated with Natick, Massachusetts, in the Boston area. This expansion gave the company a presence in a major biomedical and academic region and complemented its Italian operations in Busto Arsizio and Milan. The company’s international footprint also included a subsidiary or operating presence in Lugano, Switzerland. Together, the Italian, Swiss, and U.S. locations indicate an organization structured to serve customers and research relationships across multiple jurisdictions. The available material does not provide a full corporate history, ownership timeline, financial record, or details of the precise legal relationships among these locations. Scientific collaboration became another important part of Biocell Center’s identity. The company has been described as collaborating with Harvard University and the Caritas Christi Health Care hospital network on research into amniotic stem cells. Such activity connected its private banking operations with broader investigations into the biological properties and possible medical applications of cells derived from amniotic fluid. The references do not establish that these collaborations resulted in an approved treatment or a commercially available therapeutic product. The company’s Italian headquarters operations have been associated with president Marco Reguzzoni and scientific director Giuseppe Simoni. Beyond these identified leadership roles, the supplied sources provide limited information about the company’s later management, business performance, regulatory status, or operational scale. Accordingly, the documented history is strongest for the company’s early banking milestones, international locations, and research partnerships rather than for its subsequent corporate development.

• 2009

  Opening of the first reported U.S. private amniotic stem-cell bank

  [1]Biocell Centeren.wikipedia.org

  The company opened a U.S. facility for private storage of stem cells obtained during genetic amniocentesis. The operation was associated with Natick, Massachusetts, in the Boston area.

• 2008

  Opening of the first reported amniotic-fluid stem-cell bank

  [1]Biocell Centeren.wikipedia.org

  Biocell Center opened what reference material describes as the first amniotic-fluid stem-cell bank in the world, establishing its early specialization in dedicated preservation infrastructure for this type of biological material.

A specialized international provider of private amniotic-fluid stem-cell banking and related research services, positioned at the intersection of prenatal healthcare, biological preservation, and regenerative-medicine research.

• Private biological storage · 2008

  Amniotic-fluid stem-cell banking

  Biocell Center’s core offering is the private preservation of stem cells collected from amniotic fluid. The service encompasses the handling and cryogenic storage of biological samples, particularly material obtained during genetic amniocentesis. The available references describe the banking activity but do not specify storage terms, pricing, contractual duration, or technical performance metrics.

• Laboratory service

  Amniotic-fluid sample collection and processing

  The company’s banking model depends on the collection and laboratory processing of amniotic-fluid material before cryopreservation. These activities connect prenatal clinical procedures with specialized biological sample management. The supplied material does not provide a detailed description of the laboratory protocol, sample-release process, or applicable regulatory certifications.

• Research service and partnership

  Amniotic stem-cell research collaborations

  Biocell Center has participated in collaborations involving research on amniotic stem cells, including relationships identified with Harvard University and the Caritas Christi Health Care hospital network. These activities concern scientific investigation rather than a named consumer product or approved medicine. The available sources do not specify the individual studies, funding arrangements, or resulting intellectual property.

• 2009

  Expansion of private banking services into the United StatesStrategy

  Background

  Following the reported establishment of its first dedicated bank in 2008, Biocell Center sought to extend its specialized service model beyond Italy.

  Action taken

  The company opened a U.S. amniotic-fluid stem-cell bank in the Boston-area community of Natick, Massachusetts, for private storage of material obtained during genetic amniocentesis.

  Aftermath

  The expansion gave Biocell Center a presence in the U.S. biomedical market. The supplied sources do not provide later operating or financial results.

  Source

• 2008

  Entry into dedicated amniotic-fluid stem-cell bankingStrategy

  Background

  The company operated in an emerging area distinct from conventional cord-blood banking, with a focus on stem cells derived from amniotic fluid.

  Action taken

  Biocell Center opened a dedicated amniotic-fluid stem-cell bank and developed a private preservation model around samples collected during prenatal genetic amniocentesis.

  Aftermath

  The move established the company as an early specialist in amniotic-fluid stem-cell banking and provided the basis for later international expansion.

  Source

1. 1Biocell Centeren.wikipedia.org